Sanitas AB
Sanitas, AB sells HBM Pharma s.r.o
Sanitas AB / 09.07.2010 08:02 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- On July 8, 2010 Lithuanian-domiciled Central and Eastern European (CEE) specialty pharmaceutical company Sanitas, AB sold its 100% shareholding in subsidiary HBM Pharma s.r.o in Slovakia to Latvian company Liplats 2000, SIA. HBM Pharma was primarily engaged in toll manufacturing activities and the entity has been sold with all of its existing toll manufacturing contracts. As previously announced, sales, marketing and regulatory divisions in Slovakia and the Czech Republic were separated from HBM Pharma and retained in Sanitas Group prior to the divestment. Sanitas acquired HBM Pharma (previously named Hoechst Biotika) from Sanofi Aventis in July 2005. The entity was integrated into Sanitas Group as a manufacturing unit and a hub to start sales and marketing activities in neighboring countries.This divestment will allow Sanitas to optimize its manufacturing capacity, while freeing resources to reduce leverage, focus on its own product portfolio and continue its roll-out of new branded generic pharmaceuticals in its focus therapeutic niches. Legal and Corporate Affairs Director Ruta Milkuviene +370 37 22 67 25 News Source: NASDAQ OMX 09.07.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Sanitas AB Lithuania Phone: Fax: E-mail: Internet: ISIN: LT0000106171 WKN: End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden